December 11, 2021Open Access

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

FLFrederick L. LockeMoffitt Cancer Center DMDavid B. MiklosPalo Alto University CJCaron A. JacobsonDana-Farber Cancer Institute

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Axi-cel therapy led to significant improvements, as compared with standard care, in event-free survival and response, with the expected level of high-grade toxic effects. (Funded by Kite; ZUMA-7 ClinicalTrials.gov number, NCT03391466.).

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Locke et al. (Sat,) studied this question.

synapsesocial.com/papers/69df0849d5404a0bea591828 https://doi.org/https://doi.org/10.1056/nejmoa2116133

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)2021 · 77 citations
2Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)2017 · 181 citations
3Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study2014 · 1,262 citations
4Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial2018 · 2,274 citations
5Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma2017 · 624 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo